- * HEMGENIX Cohort:
- * \- Treatment with commercial HEMGENIX.
- * \- Have provided signed written informed consent within 3 months before or within 6 months after HEMGENIX treatment, or within 6 months of when the study is initiated at the participating site.
- * FIX Prophylaxis Cohort:
- * \- Adult patients (≥ 18 years) with hemophilia B who have consented and enrolled in ATHN Transcends Hemophilia Cohort (or a similar registry) and are receiving FIX prophylaxis therapy.
Hemophilia B
An Observational Cohort Study to Characterize the Effectiveness and Safety of HEMGENIX® in Patients With Hemophilia B
NCT06008938 | OBSERVATIONAL
This observational, post-authorization, long-term follow-up study aims to investigate the short and long-term effectiveness and safety of HEMGENIX in patients with hemophilia B. The study will also include a cohort of patients with hemophilia B treated with FIX prophylaxis to enable interpretation of relevant efficacy and safety findings of HEMGENIX.
Trial Information
If interested, contact clinicaltrials@cslbehring.com or +1 610-878-4697 for more information
CSL Behring respects your privacy. For an explanation of how CSL Behring will use the information you are submitting, please view our Privacy Policy
American Thrombosis and Hemostasis Network
Rochester,New York,United States,14604
Medical University Vienna
Vienna,New York,Austria,14604
Aarhus Universitetshospital
Århus N,New York,Denmark,14604
Centre Hospitalier Universitaire de Brest CHU Morvan
Brest,New York,France,14604
Centre Rgional de Traitement de l'Hmophilie
Nantes,New York,France,14604
CHU Nancy Hpital Brabois
Vandœuvre-lès-Nancy,New York,France,14604
Klinik fr Angiologie Hmostaseologie
Berlin,New York,Germany,14604
Hannover Medical School
Hanover,New York,Germany,14604
University Hospital Bern Inselspital
Bern,New York,Switzerland,14604
Study Eligibility Criteria
Additional Studies
Additional studies can be found at ClinicalTrials.gov